ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cost-Effectiveness"

  • Abstract Number: 1001 • ACR Convergence 2023

    Distance Not Travelled in a Tele-Rheumatology Shared Care Model: Leveraging the Expertise of an Advanced Clinician Practitioner in Arthritis Care (ACPAC)-trained Extended Role Practitioner (ERP) in Rural-remote Ontario

    Amanda Steiman1, Jocelyne Murdoch2, Rachel Shupak3, Taucha Inrig4 and Katie Lundon5, 1Sinai Health System, Toronto, ON, Canada, 2Arthritis Society, Toronto, ON, Canada, 3St. Michael's Hospital/University of Toronto, Toronto, ON, Canada, 4St. Michael's Hospital, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: A shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…
  • Abstract Number: 1840 • ACR Convergence 2023

    Value of Various Intra-Articular Injections for Knee Osteoarthritis Management

    Hanna Mass1, Jamie Collins1, david Hunter2, Catherine Yang1, Morgan Jones1, Stephen Messier3, Tuhina Neogi4, A. David Paltiel5, Jeffrey Katz1 and Elena Losina6, 1Brigham and Women's Hospital, Boston, MA, 2Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, 3Wake Forest University, Winston-Salem, NC, 4Boston University School of Medicine, Boston, MA, 5Yale School of Public health, New Haven, CT, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
  • Abstract Number: 2002 • ACR Convergence 2023

    Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Yamei Wang4, Leny Pearman4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Boston, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
  • Abstract Number: 0058 • ACR Convergence 2022

    Health System Improvement in Inpatient ANA and Serologic Test Utilization

    Saloni Goyal1, Yasin kanakrieh1, Marie O'Brien1, Amy Slenker1, Kathryn Zaffiri1 and James Ross2, 1Lehigh Valley Health Network, Allentown, PA, 2lvhn, Macungie, PA

    Background/Purpose: In 2005 Lehigh Valley Health Network (LVHN) instituted order sets for ANA serologic reflex testing with the objective to facilitate more efficient patient work-up…
  • Abstract Number: 0060 • ACR Convergence 2022

    Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission

    Jeffrey Curtis1, Kathleen Fox2, Fenglong Xie3, Yujie Su3, David Collier4, Cassie Clinton3 and Hafiz Oko-osi5, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Strategic Health (formerly with Amgen), Thousand Oaks, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Amgen Inc., Simi Valley, CA, 5Gilead Sciences, Foster City, CA

    Background/Purpose: Rheumatoid arthritis (RA) affects about 1-2% of adults with annual US costs at $19 billion. Most studies evaluating cost of care have not had…
  • Abstract Number: 0726 • ACR Convergence 2022

    Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care

    Julia Harris1, Leslie Favier2, Emily Fox3, Michael Holland3, Cara Hoffart3, Maria Ibarra3, Jordan Jones3, Luke Harris1 and Ashley Cooper3, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Leawood, KS, 3Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Most children with juvenile idiopathic arthritis (JIA) are treated with medications that require medication safety monitoring labs. Recommended laboratory testing includes a creatinine level.…
  • Abstract Number: 0746 • ACR Convergence 2022

    Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial

    Ho SO1, Evelyn Chow2, Isaac Cheng1, Xerox Lau2, Tena Li1, Cheuk Chun Szeto2 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
  • Abstract Number: 1286 • ACR Convergence 2022

    Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

    Joad Eseddi1, DeAnne Carmichael2, Shannon Wishin3 and Puneet Bajaj2, 1UT Southwestern School of Medicine, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
  • Abstract Number: 1312 • ACR Convergence 2022

    Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Leny Pearman4, jake Mathew4, Yamei Wang4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Waltham, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
  • Abstract Number: 1056 • ACR Convergence 2021

    Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study

    Mirhelen Mendes de Abreu1, Vander Fernandes2, Odirlei Andre Monticielo3, Alexandre Cristovão Maiorano1, Fernando dos Santos Beserra1, Flavia Rachel Moreira Lamarão4, Nathalie David4, Bruna de Veras4, Magda Araujo4, Blanca Elena Rios Gomes Bica5, Dalianna Luise Andrade Souto Rodrigues2, Guilherme Andrade Bulbol6, Natalia Jardim Martins da Silva7, Domingos Sávio Nunes de Lima6 and Marta Maria das Chagas Medeiros7, 1Faculdade de Medicina, Universidade Federal do Rio de Janeiro; MAPEAR Laboratory, Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 2Universidade de Cuiabá, Cuiabá, Brazil, 3Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 4GlaxoSmithKline, Medical Department, Rio de Janeiro, Brazil, 5Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 6Hospital Universitário Getúlio Vargas, Universidade Federal do Amazonas, Manaus, Brazil, 7Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brazil

    Background/Purpose: This study evaluated the patterns of care, access and direct costs related to the management and treatment of patients with systemic lupus erythematosus (SLE)…
  • Abstract Number: 1129 • ACR Convergence 2021

    Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity

    Aleksandra Kostic1, Valia Leifer2, Tuhina Neogi3, David Hunter4, Lisa Suter5, Faith Selzer6, Jeffrey Katz1 and Elena Losina7, 1Brigham and Women's Hospital, Brookline, MA, 2The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Institute of Bone and Joint Research, University of Sydney, St Leonards, Australia, 5Yale School of Medicine, New Haven, CT, 6Brigham and Women's Hospital, Amesbury, MA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Class III obesity, defined by BMI >40kg/m2, is linked to increased risk of complications post total knee replacement (TKR). This has led to recommendations…
  • Abstract Number: 1269 • ACR Convergence 2021

    The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)

    Shannon Grabich1, Eilleen Farrelly2, Robert Ortmann3, Michael Pollack4 and Sandra Sze-jung Wu4, 1Xcenda, Durham, NC, 2Xcenda, Carrollton, TX, 3AstraZeneca, Greenwood, IN, 4AstraZeneca, Wilmington, DE

    Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
  • Abstract Number: 0135 • ACR Convergence 2021

    Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression

    Joseph Couto1, Elisea Avalos-Reyes2, Amanda McCarthy3, Olga Matlin4, Michele Hamburger5, Gerard Maher6 and Kjel Johnson1, 1CVS Health, Lincoln, RI, 2CVS Health, Irving, TX, 3CVS Health, Greensboro, GA, 4CVS Health, Northbrook, IL, 5Frances Hamburger Institute, Hauppauge, NY, 6Frances Hamburger Institute, Hauppaugue, NY

    Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
  • Abstract Number: 0143 • ACR Convergence 2021

    Economic and Healthcare Resource Use Burden of Systemic Sclerosis

    Dinesh Khanna1, Dan Furst2, Justin Li3, Qian Meng4, Tamara Lesperance5, Kenyatta Peoples6, Farah Ali5, Brian LaMoreaux5 and Stephanie Taylor7, 1University of Michigan, Ann Arbor, MI, 2University of California Los Angeles, Los Angeles, CA, 3Trinity Partners, Waltham, MA, 4Trinity Life Sciences, Waltham, MA, 5Horizon Therapeutics plc, Deerfield, IL, 6Horizon Therapeutics plc, Lake Forest, IL, 7Horizon Therapeutics plc, Whitehouse Station, NJ

    Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
  • Abstract Number: 0228 • ACR Convergence 2021

    Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research

    Vladislav Tsaltskan1, Katherine Nguyen1, Christina Eaglin1, Kevin Deane2, V. Michael Holers3 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2University of Colorado Denver, Denver, CO, 3University of Colorado, Denver, CO

    Background/Purpose: Standard methods of recruitment for clinical research, such as traditional media advertisements, can be inefficient and expensive, especially for underserved communities and asymptomatic individuals.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology